Hengrui Pharmaceuticals Receives NMPA Clearance for HRS-5635 in Chronic HBV
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received clinical clearance...
Company
Fosun Pharma’s Henlius Strikes Deal with Sandoz for Global Rights to HLX13 Biosimilar
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that its subsidiary...
AstraZeneca’s Q1 2025 Results: 10% Revenue Growth, Oncology Segment Shines
UK-based AstraZeneca (NASDAQ: AZN) released its Q1 2025 financial results, showing a 10% year-on-year (YOY)...
Pfizer’s Q1 2025 Results: Revenues Down 6% YOY Amid Paxlovid, IRA Impact
US-based Pfizer Inc. (NYSE: PFE) released its Q1 2025 financial results, showing a -6% year-on-year...
United Imaging Healthcare Reports 9.73% Revenue Decline in 2024 Financials
China-based device giant United Imaging Healthcare (UIH, SHA: 688271) released its 2024 financial report, recording...
Innovent Biologics Expands Clinical Partnership with ImmVirX to Include Hepatocellular Carcinoma
China-based Innovent Biologics Inc. (HKG: 1801) announced the expansion of its existing clinical cooperation and...
Boehringer Ingelheim’s Zongertinib Shows Promising Results in HER2-Mutant NSCLC Trial
German pharmaceutical giant Boehringer Ingelheim has released the latest results from the Beamion LUNG-1 trial,...
Kangpu Biopharmaceuticals Receives NMPA Approval for KPG-818 Phase IIb Study in SLE
China-based Kangpu Biopharmaceuticals, Ltd announced that it has received approval from the National Medical Products...
WuXi AppTec Reports 21.0% YOY Revenue Growth in Q1 2025
China-based Contract Research Organization (CRO) WuXi AppTec (SHA: 603259, HKG: 2359) released its financial report...
Frontera Therapeutics’ Gene Therapy FT-017 Gains Clinical Trial Approvals for HCM
Sino-US biotech company Frontera Therapeutics, Inc. announced that its recombinant adeno-associated virus (rAAV) gene therapy...
Johnson & Johnson’s TAR-200 Shows Promising Results in Phase IIb SunRISe-1 Study for Bladder Cancer
US giant Johnson & Johnson (J&J; NYSE: JNJ) has released the first results from Cohort...
Regeneron’s Lynozyfic Gains EC Conditional Approval for Relapsed Multiple Myeloma
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that it has received conditional marketing authorization from the...
BeiGene’s Sonrotoclax NDA Accepted by NMPA for CLL/SLL Treatment
BeiGene, Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), a China-based oncology specialist proposing to change...
Shanghai Pharmaceuticals Posts Modest Q1 Revenue Growth, Sees Profit Decline
China’s Shanghai Pharmaceuticals (SPH, HKG: 2607, SHA: 601607) released its Q1 2025 financial results, showing...
OUR United Corporation Files for IPO in Hong Kong Stock Exchange
China-based OUR United Corporation, a leading provider of radiosurgical solutions, has filed for an initial...
Henlius Biotech’s HLX22 Receives Clinical Trial Approval in Germany for HER2-Positive Cancers
China-based Shanghai Henlius Biotech Inc. (HKG: 2696) announced that it has received clinical trial approval...
GenScript to Acquire Additional Stake in Probio Cayman for USD 225.1 Million
GenScript Biotech Corporation (HKG: 1548) is set to acquire an additional 300 million Class A...
CSPC Pharmaceutical Reports 7.8% Revenue Decline in 2024 Amid VBP Impact
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) reported its 2024 financial results, showing a 7.8%...
Innovent Biologics Posts 51.8% YOY Revenue Growth in 2024 Financial Report
China-based Innovent Biologics, Inc. (HKG: 1801) released its 2024 financial report, highlighting a robust growth...
Hengrui Pharmaceuticals Gains NMPA Clinical Clearance for Camrelizumab in Acral Melanoma
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received clinical clearance...